Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, Kiladjian JJ.

J Nucl Med. 2017 Oct;58(10):1603-1608. doi: 10.2967/jnumed.116.188508. Epub 2017 Mar 30.

2.

An optimised radiolabel procedure to prepare (99m)Tc-colloidal rhenium sulphide to improve radiochemical purity.

Hosten B, Roche R, Barre E, Fouque J, Mouraeff Y, Dumont A, Meur CL, Garrigue H, Hassoun S, Nataf V, Smadja C, de Beco V, Felice K, Rizzo-Padoin N.

Curr Radiopharm. 2011 Apr;4(2):144-9.

PMID:
22191654
3.

[Fluorine-18 in radiopharmacy].

de Beco V, Le Bars D, Scherrmann JM.

Ann Pharm Fr. 2008 Jan;66(1):60-5. doi: 10.1016/j.pharma.2007.12.002. Epub 2008 Mar 28. Review. French.

PMID:
18435989
4.

Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass?

Cassinat B, Laguillier C, Gardin C, de Beco V, Burcheri S, Fenaux P, Chomienne C, Kiladjian JJ; PV-Nord Group.

Leukemia. 2008 Feb;22(2):452-3. Epub 2007 Aug 23. No abstract available.

PMID:
17713549
5.

Safety of 18F-DOPA injection for PET of carcinoid tumor.

Nataf V, Balard M, de Beco V, Kerrou K, Gutman F, Grahek D, Montravers F, Talbot JN.

J Nucl Med. 2006 Oct;47(10):1732; author reply 1732. No abstract available.

6.

[Basics of PET and PET/CT imaging: instrumentation and radiopharmaceuticals for clinical diagnosis].

Talbot JN, Petegnief Y, de Beco V, Nataf V, Balard M.

Presse Med. 2006 Sep;35(9 Pt 2):1331-7. Review. French.

PMID:
16969329
7.

Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?

Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN.

J Nucl Med. 2006 Sep;47(9):1455-62.

8.

Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET.

Montravers F, Grahek D, Kerrou K, Younsi N, Petegnief Y, de Beco V, Colombet-Lamau C, Talbot JN.

Nucl Med Commun. 2004 Feb;25(2):105-13.

PMID:
15154697
9.

Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F, Balogova S, Colombet C, De Beco V, Talbot JN.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1266-9. Epub 2003 Jul 10.

PMID:
12856157
10.

[Value of [18F]-fluorodeoxyglucose (FDG) positron emission tomography in digestive cancerology].

Montravers F, Kerrou K, Grahek D, Zerbib E, Mabille L, Younsi N, Petegnief Y, De Beco V, Colombet-Lamau C, Talbot JN.

Presse Med. 2002 Oct 12;31(33):1560-8. Review. French.

PMID:
12422485
11.

[(18F)-fluoro-2-deoxyglucose PET in imaging of gynecologic cancers].

Talbot JN, Grahek D, Kerrou K, Younsi N, de Beco V, Colombet-Lamau C, Petegnief Y, Cailleux N, Montravers F.

Gynecol Obstet Fertil. 2001 Nov;29(11):775-98. Review. French.

PMID:
11770272
12.

[[18F]-fluorodeoxyglucose scintigraphy in digestive cancer].

Montravers F, Grahek D, Kerrou K, De Beco V, Younsi N, Talbot JN.

Gastroenterol Clin Biol. 2001 Apr;25(4 Suppl):B191-6. Review. French. No abstract available.

13.

32. Detection of Recurrence of Ovarian Cancer using

Kerrou K, Montravers F, Grahek D, Younsi N, de Beco V, Talbot JN.

Clin Positron Imaging. 2000 Jul;3(4):186.

PMID:
11150789
14.
15.

14. FDG CDET (2D Dual-Head Coincidence Gamma Camera) in the Primary Staging of Oesophageal Cancer. Histopathological Correlation.

Montravers F, Grahek D, Kerrou K, de Beco V, Younsi N, Barrier A, Houry S, Lacaine F, Huguier M, Talbot JN.

Clin Positron Imaging. 2000 Jul;3(4):168.

PMID:
11150771
16.

Assessment of malignancy in pulmonary lesions: FDG dual-head coincidence gamma camera imaging in association with serum tumor marker measurement.

Bousson V, Moretti JL, Weinmann P, Safi N, Tamgac F, Groiselle C, de Beco V, Hillali Y, Valeyre D, Breau JL.

J Nucl Med. 2000 Nov;41(11):1801-7.

17.

Effect of cyclodextrin complexation on the in vivo disposition of the brain imaging radiopharmaceutical 99mTechnetium ethyl cysteinate dimer (99mTc-ECD).

Oliver DW, Dormehl IC, Louw W, Kilian E, de Beco V, Morretti JL.

Arzneimittelforschung. 2000 Aug;50(8):758-64.

PMID:
10994161
18.

Uptake of liposome-encapsulated 99Tcm-MIBI by sensitive and multidrug-resistant tumour cell lines.

Cordobes MD, Moretti JL, de Beco V, Benazzouz F, Starzec A.

Nucl Med Commun. 1999 May;20(5):433-7.

PMID:
10404528
19.

Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.

Moretti JL, Duran Cordobes M, Starzec A, de Beco V, Vergote J, Benazzouz F, Boissier B, Cohen H, Safi N, Piperno-Neumann S, Kouyoumdjian JC.

J Nucl Med. 1998 Jul;39(7):1214-8.

20.

Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes.

Berson A, De Beco V, Lettéron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, Pessayre D.

Gastroenterology. 1998 Apr;114(4):764-74.

PMID:
9516397
21.

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.

Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C.

Antimicrob Agents Chemother. 1993 Feb;37(2):281-6.

Supplemental Content

Loading ...
Support Center